Tedizolid Phosphate
(Synonyms: 磷酸特地唑胺; TR-701FA) 目录号 : GC45006A prodrug form of tedizolid
Cas No.:856867-55-5
Sample solution is provided at 25 µL, 10mM.
Tedizolid phosphate is a prodrug form of tedizolid, an antibiotic with activity against Gram-positive bacteria. Tedizolid phosphate is rapidly converted by non-specific phosphatases to tedizolid, which inhibits the growth of S. aureus, S. epidermidis, E. faecalis, E. faecium, S. pneumoniae, and S. pyogenes (MICs = 0.25-1 μg/ml). In vivo, tedizolid phosphate (15 mg/kg) reduces vegetation titer in a rabbit model of aortic valve endocarditis caused by methicillin-resistant S. aureus (MRSA). It also reduces densities of methicillin-susceptible S. aureus and MRSA infection in a mouse model of catheter-related biofilm infection and increases survival in a rabbit model of MRSA necrotizing pneumonia.
Animal experiment: | To induce a systemic S. pneumoniae infection, male ICR mice (weight, 18 to 20 g) are inoculated intraperitoneally with 1 of 4 PRSP isolates (DR9, DR10, DR11, or DR14) suspended in 10% mucin. The suspension contained sufficient bacteria to kill 100% of untreated control mice. At 1 h postinfection, mice receives a single dose of either tedizolid phosphate or linezolid, and survival is assessed daily for 7 days postinfection. Treatments are delivered both orally and intravenously at each of four doses (40 mg/kg of body weight, 13.33 mg/kg, 4.44 mg/kg, and 1.48 mg/kg), with 8 mice per group defined by dose, delivery method, and infecting strain. The 50% effective dose (ED50), i.e., the dose allowing survival of 50% of the infected mice, is calculated for each delivery route using probit analysis. |
References: [1]. Choi S, et al. Activity of Tedizolid Phosphate (TR-701) in Murine Models of Infection with Penicillin-resistant and Penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother. 2012 Jun 19. |
Cas No. | 856867-55-5 | SDF | |
别名 | 磷酸特地唑胺; TR-701FA | ||
Canonical SMILES | FC1=C(C2=CN=C(C3=NN(C)N=N3)C=C2)C=CC(N4C(O[C@@H](COP(O)(O)=O)C4)=O)=C1 | ||
分子式 | C17H16FN6O6P | 分子量 | 450.3 |
溶解度 | PBS (pH 7.2): 1 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2207 mL | 11.1037 mL | 22.2074 mL |
5 mM | 0.4441 mL | 2.2207 mL | 4.4415 mL |
10 mM | 0.2221 mL | 1.1104 mL | 2.2207 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet